New drug may unmask hidden leukemia cells after treatment
NCT ID NCT07392970
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 5 times
Summary
This early study tests whether a single injection of motixafortide can help reveal tiny amounts of leukemia cells that remain after initial chemotherapy in people with acute myeloid leukemia (AML). Ten adults who have completed 1-2 cycles of treatment will receive the drug and then have blood tests to see if hidden cancer cells become easier to detect. The goal is to improve measurement of residual disease, not to treat the leukemia itself.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?